Skip to main content

KPMG Deal Capsule Life Sciences Februar 2022

Page 1

Deal Capsule Transactions in Life Sciences February 2022

With a confident rebound in the beginning of 2021, Life Sciences M&A activity slowed down in Q4 2021 due to the emergence of the Omicron variant of Covid19. Moderated valuations, portfolio optimization via bolt-on acquisitions and divestments of non-core business segments are expected to drive the M&A landscape going forward.

CHRISTIAN KLINGBEIL | PARTNER, KPMG IN GERMANY

HIGHLIGHTS — Life sciences’ M&A activity grew to another record high in terms of deal volume in 2021 marked by steady growth in the biotech and medical devices & diagnostics subsectors. — Deal value likewise rose significantly led by biotech accounting for seven of the top ten life sciences deals - despite having highest valuations amongst all the sub-sectors.

Trends in Life Sciences M&A

Y-o-Y Volume Value +34%

4.000

597

467

3.000 2.000 1.000

2,449

296

265

222

2,530

2,611

2,832

2016

2017

2018

285

+42% 406

2,768

3,161

4,223

2019

2020

2021

0 2015

Number of Announced Deals

Deal Value in US$ bn.

Subsector public EBITDA multiples(a) — Valuations continued to normalise in Q4 2021 for all the subsectors except biotech, due to heightened uncertainty on account of the resurgence of the corona virus and expected increase in interest rates by central banks.

Biotech

Pharmaceuticals 24.8x

14.1x

Medical devices & diagnostics 25.5x

13.8x

Q3 2021

Q4 2021

Q3 2021

Q4 2021

17.9x

Q3 2021

17.5x

Q4 2021

Deal Thermometer 2021 — KPMG’s Deal Thermometer indicates a favorable environment for deal activities in the life sciences sector.

DEAL APPETITE (Forward P/E ratio)

HOT

DEAL CAPACITY (Net Debt/EBITDA)

MODERATE 22.3

31 Dec 2021 31 Dec 2022

Note: Source:

0.8x

21.8 (b)

COOL

0.4x

31 Dec 2021 31 Dec 2022

(c)

(a) Refers to 90% quantile at respective quarter-end (b) Forward P/E ratio: net profit expected for 2022 to market cap in 2021 (c) Deal capacity: expected net debt to EBITDA in 2022 Thomson One, Capital IQ, KPMG Germany Analysis

© 2022 KPMG AG Wirtschaftsprüfungsgesellschaft, a corporation under German law and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

1


Turn static files into dynamic content formats.

Create a flipbook